Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Hillevax Inc HLVX

Healthcare Biotechnology
HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing vaccines. The Company's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by... see more

Recent & Breaking News (NDAQ:HLVX)

HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress

GlobeNewswire March 20, 2024

HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference

GlobeNewswire February 5, 2024

HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer

GlobeNewswire January 18, 2024

HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China

GlobeNewswire January 8, 2024

HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 3, 2024

HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

GlobeNewswire November 9, 2023

HilleVax to Present at Upcoming Investor Conferences

GlobeNewswire November 1, 2023

HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

GlobeNewswire September 26, 2023

HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

GlobeNewswire September 25, 2023

HilleVax Announces Pricing of Public Offering of Common Stock

GlobeNewswire September 19, 2023

HilleVax Announces Proposed Public Offering of Common Stock

GlobeNewswire September 19, 2023

HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress

GlobeNewswire August 14, 2023

HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

GlobeNewswire May 12, 2023

HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors

GlobeNewswire May 9, 2023

HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate

GlobeNewswire April 25, 2023

HilleVax Reports Full Year 2022 Financial Results and Highlights Recent Company Progress

GlobeNewswire March 17, 2023

HilleVax Announces Executive Management Appointments and Promotions

GlobeNewswire January 9, 2023

HilleVax to Present at the 41st Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2023

HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate

GlobeNewswire December 5, 2022

HilleVax to Participate in November Investor Conferences

GlobeNewswire November 10, 2022